Celularity Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 115

Employees

  • Stock Symbol
  • CELU

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $0.46
  • (As of Friday Closing)

Celularity General Information

Description

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.

Contact Information

Formerly Known As
Anthrogenesis
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 170 Park Avenue
  • Florham Park, NJ 07039
  • United States
+1 (908)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 170 Park Avenue
  • Florham Park, NJ 07039
  • United States
+1 (908)

Celularity Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celularity Stock Performance

As of 20-Nov-2026, Celularity’s stock price is $0.46. Its current market cap is $15M with 32.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.46 $0.47 $0.42 - $2.55 $15M 32.5M 3.89M -$1.69

Celularity Financials Summary

As of 30-Jun-2026, Celularity has a trailing 12-month revenue of $18.7M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 52,033 98,652 115,695 106,771
Revenue 18,666 26,550 54,220 22,771
EBITDA (36,386) (77,926) (44,037) (184,266)
Net Income (45,858) (91,716) (57,892) (196,295)
Total Assets 96,167 107,329 132,682 143,889
Total Debt 36,021 40,901 68,836 65,417
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Celularity Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell t
Drug Discovery
Florham Park, NJ
115 As of 2025

San Diego, CA
 

New Haven, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celularity Competitors (92)

One of Celularity’s 92 competitors is Fate Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fate Therapeutics Formerly VC-backed San Diego, CA
Arvinas Formerly VC-backed New Haven, CT
uniQure Formerly VC-backed Amsterdam, Netherlands
Mesoblast Corporation Melbourne, Australia
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 92 competitors. Get the full list »

Celularity Patents

Celularity Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025160465-A1 A method of treating signs or symptoms of the aging process Pending 26-Jan-2024
WO-2025137471-A1 Decellularized placenta extracellular matrix and uses thereof Inactive 20-Dec-2023
WO-2025024825-A1 Decellularized placental extracellular matrix and uses thereof Inactive 26-Jul-2023
WO-2024197316-A1 Bone growth composition Inactive 23-Mar-2023
WO-2024167694-A2 Placental extracellular matrices for ocular delivery of ophthalmic therapeutic agents Inactive 06-Feb-2023 A61K9/0051
To view Celularity’s complete patent history, request access »

Celularity Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celularity Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Celularity‘s full profile, request access.

Request a free trial

Celularity Investments & Acquisitions (7)

Celularity’s most recent deal was a Seed Round with DefEYE for . The deal was made on 31-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DefEYE 31-Oct-2025 Seed Round Surgical Devices
Sequence LifeScience (Rebound Matrix) 09-Oct-2024 Corporate Asset Purchase Buildings and Property
LifebankUSA 23-Feb-2024 Merger/Acquisition Other Healthcare Services
GX Acquisition 16-Jul-2021 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Caricord 31-Aug-2018 Merger/Acquisition Other Healthcare Services
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Celularity ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.89 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Celularity’s complete esg history, request access »

Celularity Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
LifebankUSA Florham Park, NJ 1996

Celularity FAQs

  • When was Celularity founded?

    Celularity was founded in 1998.

  • Where is Celularity headquartered?

    Celularity is headquartered in Florham Park, NJ.

  • What is the size of Celularity?

    Celularity has 115 total employees.

  • What industry is Celularity in?

    Celularity’s primary industry is Drug Discovery.

  • Is Celularity a private or public company?

    Celularity is a Public company.

  • What is Celularity’s stock symbol?

    The ticker symbol for Celularity is CELU.

  • What is the current stock price of Celularity?

    As of 20-Nov-2026 the stock price of Celularity is $0.46.

  • What is the current market cap of Celularity?

    The current market capitalization of Celularity is $15M.

  • What is Celularity’s current revenue?

    The trailing twelve month revenue for Celularity is $18.7M.

  • Who are Celularity’s competitors?

    Fate Therapeutics, Arvinas, uniQure, Mesoblast, and Sangamo Therapeutics are some of the 92 competitors of Celularity.

  • What is Celularity’s annual earnings per share (EPS)?

    Celularity’s EPS for 12 months was -$1.69.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process